Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial

CONCLUSIONS: In patients with ADPKD, octreotide-LAR added-on tolvaptan reduced GFR more effectively than octreotide-LAR and placebo. Octreotide-LAR also reduced total and cystic kidney volumes and attenuated the acquaretic effect of tolvaptan.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Tolvaptan-Octreotide LAR Combination in ADPKD (TOOL), NCT03541447.PMID:36754009 | DOI:10.2215/CJN.0000000000000049

Source: Clinical Journal of the American Society of Nephrology : CJASN - February 8, 2023 Category: Urology & Nephrology Authors: Matias Trillini Anna Caroli Norberto Perico Andrea Remuzzi Paolo Brambilla Giulia Villa Annalisa Perna Tobia Peracchi Nadia Rubis Davide Martinetti Mariarosa Caruso Valentina Fanny Leone Daniela Cugini Fabiola Carrara Giuseppe Remuzzi Piero Ruggenenti TOO Source Type: research